An internal task force formed to investigate conflicts of interest at Memorial Sloan Kettering Cancer Center has produced three initial recommendations that codify the moratoria that were put in place after multiple ethics transgressions at the cancer center were revealed by The New York Times and ProPublica last fall.
Last week, FDA granted accelerated approval to Replimune Group Inc. for it’s biologic, RP1 (vusolimogene oderparepvec), following the FDA Cellular, Tissue, and Gene Therapies Advisory Committee’s 10:3 vote in support of the biologic in combination with nivolumab for the treatment of advanced melanoma in patients who have progressed on prior anti-PD-1 therapy.
